Document 0284
 DOCN  M9590284
 TI    Antiretroviral drugs acting late in the HIV replication cycle.
 DT    9509
 AU    Birch C; Victorian Infectious Diseases Reference Laboratory, Fairfield;
       Hospital.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:230 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291815
 AB    Most antiretroviral drugs available for treatment of HIV infection are
       targeted at the reverse transcriptase, an enzyme acting relatively early
       (pre-integration) in the HIV replication cycle. There is a need for
       drugs directed at other sites, and the HIV protease and Tat gene product
       are potential targets. Both provide essential functions at a
       post-integration level. The HIV Tat gene product has not been widely
       exploited, and clinical trials with Tat inhibitors have been
       disappointing. The potential for, and problems associated with, the use
       of Tat inhibitors in the treatment of HIV infection will be discussed.
       Several protease inhibitors are in pre-clinical development or in
       clinical trials. Their mechanism of action at both the intracellular
       level and within the virion will be discussed in the light of their role
       in preventing maturation of HIV. Problems faced in the development and
       delivery of these inhibitors, and the potential for development of
       resistance to them, will also be addressed.
 DE    Antiviral Agents/*THERAPEUTIC USE  Gene Expression Regulation,
       Viral/DRUG EFFECTS  Genes, tat/DRUG EFFECTS  Human  HIV/*DRUG
       EFFECTS/GENETICS  HIV Infections/*DRUG THERAPY/VIROLOGY  Virus
       Replication/*DRUG EFFECTS/GENETICS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).